MedDataX Logo

Breast Implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Registry

NCT ID: NCT04220970

Last Updated: 2026-01-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-06-07

Study Completion Date

2032-06-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Anaplastic large cell lymphoma associated with breast implants (BIA-ALCL) is a rare disease seen only in women with a breast implant.

Because of the low incidence of this disease and the peculiar histological subtype, French authorities, in accordance with the recommendations of an expert group, recommended the implementation of a BIA-ALCL case registry, in connection with a national Multidisciplinary meeting (Réunion de Concertation Pluridisciplinaire nationale de recours- RCP).

This registry is opened in France and in Belgium

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Leukemic Phase of ALCL

NCT04908059

Anaplastic Lymphoma
UNKNOWN

Study of the Biological Mechanisms Associated With the Immunogenicity in Anaplastic Large Cell Lymphoma ( ALCL ) ALK +

NCT02902874

ALCL
COMPLETED NA

Institut Paoli Calmettes Lymphoma Database

NCT02869542

Lymphoma
RECRUITING

Acute Lymphoblastic Leukemia Registry at Asan Medical Center

NCT01761682

Leukemia, Acute Lymphoblastic Precursor B-Cell Lymphoblastic Leukemia Leukemia, Biphenotypic, Acute +2 more
TERMINATED

Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients

NCT03366272

Lymphoma, Non-Hodgkin
COMPLETED PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anaplastic Large Cell Lymphoma Associated With Breast Implants (BIA-ALCL)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

BIA-ALCL

BIA-ALCL

Intervention Type OTHER

Observational : no intervention

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BIA-ALCL

Observational : no intervention

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patients with an anaplastic large cell lymphoma associated with breast implants

Exclusion Criteria

\-
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

The Lymphoma Academic Research Organisation

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

A. Z. Sint-Jan Brugge-Oostende AV

Bruges, , Belgium

Site Status RECRUITING

Clinique Universitaire Saint LUC

Brussels, , Belgium

Site Status RECRUITING

Cliniques Universitaires de Bruxelles - Hôpital Erasme

Brussels, , Belgium

Site Status NOT_YET_RECRUITING

Institut Jules Bordet

Brussels, , Belgium

Site Status RECRUITING

Universitair Ziekenhuis Brussel

Brussels, , Belgium

Site Status NOT_YET_RECRUITING

Universitair Ziekenhuis Antwerpen

Edegem, , Belgium

Site Status NOT_YET_RECRUITING

Universitair Ziekenhuis Gent

Ghent, , Belgium

Site Status RECRUITING

U.Z. Leuven - Campus Gasthuisberg

Leuven, , Belgium

Site Status RECRUITING

CHU de Liège -Domaine Sart Tilman

Liège, , Belgium

Site Status RECRUITING

CHU UCL Namur - Site Godinne

Yvoir, , Belgium

Site Status RECRUITING

CH d Avignon - Hopital Henri Duffaut

Avignon, , France

Site Status RECRUITING

Institut Bergonié

Bordeaux, , France

Site Status RECRUITING

CHRU de Brest - Hôpital Morvan

Brest, , France

Site Status RECRUITING

Hopital Louis Pasteur

Colmar, , France

Site Status RECRUITING

APHP - Hopital Henri Mondor

Créteil, , France

Site Status RECRUITING

CHU de Dijon - Hôpital le Bocage

Dijon, , France

Site Status RECRUITING

Centre Médical la Roseraie

Lille, , France

Site Status RECRUITING

Centre Léon Bérard

Lyon, , France

Site Status RECRUITING

Institut Paoli Calmettes

Marseille, , France

Site Status RECRUITING

CH Saint-Eloi

Montpellier, , France

Site Status RECRUITING

CHU de Nantes - Hôtel Dieu

Nantes, , France

Site Status RECRUITING

Hôpital Cochin

Paris, , France

Site Status RECRUITING

CH de Pau

Pau, , France

Site Status RECRUITING

CH de Perpigan

Perpignan, , France

Site Status RECRUITING

Centre Hospitalier Lyon Sud

Pierre-Bénite, , France

Site Status RECRUITING

Chu de Reims - Hopital Robert Debre

Reims, , France

Site Status RECRUITING

Centre Henri Becquerel

Rouen, , France

Site Status RECRUITING

Centre Rene Hugenin

Saint-Cloud, , France

Site Status RECRUITING

CH de Saint Malo

St-Malo, , France

Site Status RECRUITING

CHRU de Strasbourg

Strasbourg, , France

Site Status RECRUITING

Institut Universitaire du Cancer - Oncopole Toulouse (IUCT-O)

Toulouse, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Belgium France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Manon Croix

Role: CONTACT

[email protected]
+33 (04) 72 66 93 33

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Sylvia SNAUWAERT, MD

Role: primary

[email protected]
+32 (0)50 45 23 28

Nicole STRAETMANS, MD

Role: primary

[email protected]
02 764 18 00

Virginie DE WILDE, MD

Role: primary

[email protected]
+32 2 555 31 11

Marie MAEREVOET, MD

Role: primary

[email protected]
+32 2 541 31 11

Rik SCHOTS, MD

Role: primary

[email protected]
02 477 41 11

Wilfried SCHROYENS, MD

Role: primary

[email protected]
+32 3 821 53 98

Fritz OFFNER, MD

Role: primary

[email protected]
+32(0)92402138

Ann JANSSENS, MD

Role: primary

[email protected]
+32 16 34 66 70

Christophe BONNET, MD

Role: primary

[email protected]
+32(0)43662851

Marc ANDRE, MD

Role: primary

[email protected]
081/42 38 31

Borhane SLAMA, MD

Role: primary

[email protected]
04 32 75 93 00

Fontanet BIJOU, MD

Role: primary

[email protected]
+33 05 56 33 78 32

Adrian TEMPESCUL, MD

Role: primary

[email protected]
02 98 22 33 95

Bruno AUDHUY, MD

Role: primary

[email protected]
0389124104

Corinne HAIOUN, MD

Role: primary

[email protected]
01 49 81 21 11

Jean-Noel BASTIE, MD

Role: primary

[email protected]
03 80 29 50 41

Manuel CLIQUENNOIS, MD

Role: primary

[email protected]
0320994055

Emmanuelle NICOLAS-VIRELIZIER, MD

Role: primary

[email protected]
04 78 78 28 28

Jean Marc SCHIANO, MD

Role: primary

[email protected]
04 91 22 33 33

Guillaume CARTRON, MD

Role: primary

[email protected]
+33(0)4 67 33 83 62

Béatrice MAHE, MD

Role: primary

Bénédicte DEAU FISCHER, MD

Role: primary

[email protected]
+33(0)158412132

Marcela ANITEI GHINEA, MD

Role: primary

[email protected]
05 59 72 67 96

Laurence SANHES, MD

Role: primary

[email protected]
04 68 61 89 07

Gilles SALLES, MD

Role: primary

[email protected]
04 78 86 43 40

Eric DUROT, MD

Role: primary

[email protected]
+33(0)3 26 78 36 44

Fabrice JARDIN, MD

Role: primary

[email protected]
+33 (0)2 32 08 29 09

Sylvie GLAISNER, MD

Role: primary

[email protected]
+33(0)1 47 11 15 15

Claudia BIRLADEANU

Role: primary

[email protected]
02 99 21 21 50

Elise TOUSSAINT, MD

Role: primary

[email protected]
03 88 11 67 28

Lucie Oberic, Dr

Role: primary

[email protected]
+33(0)561777666

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BIA-ALCL Registry

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Identification of Occupational Exposures in Acute Hematologic Malignancy
NCT03316209 COMPLETED
BCL6-rearrangements Implications in Non-Hodgkin Lymphomas.
NCT06424379 ACTIVE_NOT_RECRUITING
LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV)
NCT04446962 ACTIVE_NOT_RECRUITING PHASE1/PHASE2
Low Grade Lymphoma
NCT01698866 UNKNOWN PHASE4
Mediastinal Recurrence of Lympho-proliferative Disorders: a Biopsy is Needed
NCT06714045 COMPLETED
Risk and Clinical Consequences of Low Count Monoclonal B-cell Lymphocytosis (LC MBL)
NCT06416267 NOT_YET_RECRUITING
Causes of Death in Follicular Lymphoma: a Single Center Retrospective Analysis
NCT02951871 COMPLETED
National Lymphangioleiomyomatosis Registry, France
NCT01484236 RECRUITING
The ARCAN Database is Used for Retrospective Non-interventional Research Projects. The Database Collects Clinical and Laboratory Data From Patients With Lymphoid Malignancies. The Database Doesn't Require Biological Sample of Patients, it Records Only Information Based on the Patients' Medical File.
NCT03868527 RECRUITING
A Phase IB Study Of The BTKi CC-292 Combined With Lenalidomide In Adults Patients With Relapsed/Refractory B-Cell Lymphoma
NCT01766583 COMPLETED PHASE1
Assessment of Blood Biomarkers by DNA Microarrays in Patients With Aggressive Lymphoma BMS_LyTrans
NCT01287923 COMPLETED
Description of the Immune Deficiency in Patients With Untreated Chronic Lymphocytic Leukemia and Search for Predictive Factors of Infectious Risk
NCT06475469 RECRUITING NA
Molecular Prognosis of Lymphomas of the Central Nervous System (ALYCE-molecular)
NCT03859544 UNKNOWN
Living Conditions of Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma in the Côte d'Or Region
NCT04859920 COMPLETED
Tumor Registry of Lymphatic Neoplasia
NCT00889798 COMPLETED
SMOLY : Phenotype and Functions of Monocyte Subtypes in High Grade B Lymphoma: Towards New Biomarkers?
NCT03672682 COMPLETED
LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma
NCT00062868 COMPLETED PHASE1
Treatment of Localized Low Grade Lymphomas
NCT00536458 COMPLETED PHASE3
Electronic MonitorIng of Events for dIffuse Large b Cell LYmphoma
NCT05298293 NOT_YET_RECRUITING NA
Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia
NCT02618109 TERMINATED PHASE4
A Real-world Data and Sample Compendium of Frail and/or Multiply Treated Large B-cell Lymphoma
NCT07335120 RECRUITING
Mediastinal Grey Zone Lymphoma From the LYSA
NCT03037177 COMPLETED
Multiple Fields Radiotherapy Versus Intravenous Rituximab in the Treatment of Indolent Cutaneous Lymphomas B-cell With Multiple or Recurrent Lesions
NCT02867553 UNKNOWN PHASE3
Institut Paoli Calmettes Chronic Lymphatic Leukemia Database
NCT02869529 RECRUITING
Assessment of Survival and Autonomy With Rituximab Plus Chemotherapy or Rituximab Plus Lenalidomide for Elderly Patients With Relapsed Diffuse Large B-cell Lymphoma
NCT04113226 UNKNOWN PHASE2